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Effect of Cyclosporine on the Rate of Renal Ftinction Recovery After 
Renal lYansplantation"^  
Francis Dumler, MD^ 
To assess the effect of cyclosporine therapy on the rate of renal function recovery after renal 
transplantation, patients with no clinical evidence of rejection and who were treated with either 
cyclosporine or azathioprine in addition to steroid therapy were studied (n = 74). Ofthe patients with 
immediate renal function (n = 57), those receiving organs from living, related donors had a faster 
recovery rate of glomerular filtration than patients with cadaveric grafts (azathioprine, 15 ± 2 versus 
7 ± 1 mLlminlday, P = 0.0001; cyclosporine, 14 ± 3 versus 6 ± 1 mLlminlday, P = 0.001). 
Recipients of cadaveric grafts with delayed renal function (n = 17) had a decreased recovery rate of 
allograft function when treated with cyclosporine as compared to those treated with azathioprine (4 ± 
2 versus 6 ± 1 mL/min/day, respectively; P = 0.026). Patients on azathioprine achieved better renal 
function (P = 0.01) than those on cyclosporine (recipients of organs from living, related donors, 59 
± 5 versus 52 ± 3 mL/min; recipients of cadaveric grafts, 52 ± 5 versus 40 ± 2 mL/min). Thus, even 
in this early period, cadaveric-graft recipients treated with cyclosporine demonstrate an apparent 
reduction in creatinine clearance when compared to patients treated with azathioprine. (Henry Ford 
Hosp MedJ 1989:37:24-7) 
U se of cyclosporine has resulted in significant improvements in allograft survival (1-3). However, nephrotoxicity is al-
most a universal finding in cyclosporine-treated patients, rang-
ing from minor reversible decreases in renal function to chronic 
nephropathy and severe renal failure (4-7). The pathogenesis of 
acute and chronic cyclosporine-induced nephrotoxicity is not 
well defined. However, in experimental animals acute reduc-
tions in single nephron glomerular filtration rate result from re-
ductions in single nephron plasma flow and ultrafiltration coeffi-
cient associated with simultaneous increases in afferent and 
efferent arteriolar resistance (8). Cyclosporine also may worsen 
renal ischemic injury and contribute to immediate post-
transplant acute renal failure (9-11). Thus, it is important to de-
fine the effect of cyclosporine treatment on the immediate rate 
of renal function recovery in patients undergoing renal 
transplantation. 
Materials and Methods 
Patients receiving their first renal transplant between July 1, 
1982, and July 1, 1986 (n = 140) were considered eligible for 
evaluation. However, only patients with no clinical evidence of 
rejection during the time required to achieve a stable serum 
creatinine concentration were entered into the study (n = 74). 
All patients were treated with methylprednisolone (250 mg/day 
intravenously for three days) followed by oral prednisolone (0.5 
mg/kg/day). All cadaveric renal transplant recipients received 
three to five doses (17.5 to 25 mg/kg intravenously) of Min-
nesota antilymphoblast globulin starting on postoperative day 3. 
All patients received a preoperative dose of azathioprine (2 mg/ 
kg). Patients with immediate graft function, defined as urine out-
put > 1 L/day with a concomitant fall in serum creatinine con-
centration without dialysis, were either started on azathioprine 
(2 mg/kg/day) or cyclosporine-A (4 mg/kg/day intravenously) 
with conversion to oral doses (15 mg/kg/day for cadaveric-graft 
recipients and 10 mg/kg/day for recipients of organs from living, 
related donors) by postoperative day 3. In recipients with de-
layed renal function, azathioprine was continued until allograft 
function was established. Cyclosporine doses were then ad-
justed to maintain serum trough levels of 150 to 200 ng/mL for 
cadaveric-graft recipients and 100 to 150 ng/mL for recipients of 
organs from living, related donors using a polyclonal antibody 
radioimmunoassay (2). 
Serum creatinine concentrations were measured pretransplant 
and daily at 24-hour intervals. All values were corrected to the 
established posttransplant dry weight. Creatinine clearances 
were estimated daily by single-pool kinetic modeling as de-
scribed previously (12,13). The creatinine generation rates used 
for modeling were calculated as the average of values obtained 
by three separate methods (14-16). To validate this method in 
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Figure—Relationship between measured 24-hour creatinine 
clearance values and those estimated by kinetic modeling in 
nine renal transplant recipients (R = 0.959; P < 0.0001). See 
text for description of method used. 
renal transplant recipients, a subset of nine patients had 15 sepa-
rate creatinine clearances calculated simultaneously by single-
pool kinetic modeling (12,13) and by standard clearance tech-
niques during 24-hour periods. The rate of increase in renal 
function was calculated as the slope of the linear regression de-
fining the relationship between creatinine clearance values and 
days post initiation of renal allograft function. 
Unless otherwise indicated, all results are expressed as mean 
± SEM. Differences between groups were evaluated by one-
way analysis of variance and a posteriori Student t test for non-
paired samples when necessary. 
Results 
Standard creatinine clearance measurements were carried out 
in 15 independent instances in nine patients. A significant cor-
relation was found between measured and estimated creatinine 
clearances (Figure) for values ranging between 1 and 48 mL/min 
(R = 0.959; P < 0.0001; coefficient of variation = 8.26%). 
Pertinent demographic and clinical characteristics of the pa-
tients included in this study are shown in Table 1. Although the 
number of cadaveric-allograft recipients treated with 
azathioprine (n = 24) and cyclosporine (n = 32) was similar, 
the majority of patients receiving a kidney from a living, related 
donor were treated with azathioprine (n = 14) as opposed to 
cyclosporine (n = 4). For all subsequent analyses, patients were 
allocated to one of four groups according to the type of immu-
nosuppression and organ donor (Tables 2 and 3). Since age and 
weight are important factors determining endogenous creatinine 
generation, these parameters were assessed separately in the pa-
tient groups. Although cyclosporine-treated patients were older 
than those on azathioprine, no differences existed in body 
weight between treatment groups (Tables 2 and 3). 
In patients with immediate allograft function, analysis of 
variance demonstrated a significant difference (F = 5.261; P = 
Age (years): 40 ± 2 
Dry weight (kg): 62 ± 1 
Males: 41 
Females: 33 
Type 1 diabetics: 17 
Nondiabetics: 57 
Cyclosporine dose* (mg/kg/day): 10 ± 1 (36) 
Serum cyclosporine levels* (ng/mL): 165 ± 15 (36) 
*Mean of individual average values during the study period. 
Table 2 
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Parameter (n = 14) (n = 17) (n = 4) (n = 22) 
Age (years) 32 ± 3 36 ± 3 43 4 45 ± 5t 
Weight (kg)* 58 ± 3 62 ± 3 70 4 65 ± 2 
Serum creatinine 
(mg/dL)* 1.1 ± O.I 1.4 ± O.lt 1.3 ± 0.2 1.6 ± 0.1 
Creatinine clearance 
(mL/min)* 59 ± 5 52 ± 5 52 3 40 ± 2§,|| 
Rate of increase in 
creatinine clearance 
(mL/min/day) 15 ± 2 7 ± III 14 3 6 ± I# 
Days to stable creatinine 
clearance 5 ± I 8 ± 1** I 8 ± I t t 
'Values at the time when renal allograft function had stabilized. 
tp = 0.03 when compared to the azathioprine groups. 
tP = O.OI I when compared to the azathioprine. living, related group. 
§P = 0.011 when compared to the cyclosporine, living, related group. 
jjP = 0.012 when compared to the azathioprine, cadaveric group. 
IP = 0.0(X)l when compared to the azathioprine, living, related group. 
#P = O.OOI when compared to the cyclosporine. living, related group. 
**P = 0.012 when compared to the azathioprine, living, related group. 
t tP = 0.0001 when compared to the cyclosporine, living, related group. 
LR = living, related; C = cadaveric. 
0.003) in the rate of renal function recovery between patient 
groups (Table 2). However, this result was entirely accounted for 
by the higher rates in recipients of organs from living, related 
donors when compared to recipients of cadaveric grafts in both 
treatment groups (azathioprine, 15 ± 2 versus 7 ± 1 mL/min/ 
day, P = 0.0001; cyclosporine, 14 ± 3 versus 6 ± 1 mL/min/ 
day, P = 0.001). The immunosuppressive regimen used had no 
impact on the rate of renal function recovery when donor type 
was taken into account. Similar results were noted for the days 
required to achieve stable renal function (Table 2). 
Although recipients of cadaveric grafts and of organs from 
living, related donors who were treated with cyclosporine had 
higher serum creatinine concentrations than those on 
azathioprine, differences did not reach statistical significance. 
Creatinine clearance estimates were different between groups (F 
= 5.261; P = 0.003), with cyclosporine-treated recipients of 
cadaveric grafts having significantly lower creatinine clearances 
(P = 0.012) than similar recipients treated with azathioprine 
(Table 2). 
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Table 3 
Effect of Cyclosporine on the Recovery of Delayed 
Cadaveric Renal Allograft F\inction in the Immediate 
Posttransplantation Period 
Azathioprine Cyclosporine-A 
Parameter (n = 7) (n = 10) 
Age (years) 39 ± 4 48 ± 4 
Weight (kg) 55 ± 5 68 ± 4 
Serum creatinine (mg/dL)* l . I ± O.I 1.6 ± It 
Creatinine clearance (mL/min)* 55 ± 6 35 ± 3t 
Rate of increase in creatinine clearance 
(mL/min/day)* 6 ± 1 4 t I§ 
*Values at the time when renal allograft function had stabilized. 
tP = 0.041 when compared to the azathioprine group. 
tP - 0.005 when compared to the azathioprine group. 
§P = 0.026 when compared to the azathioprine group. 
All patients with delayed allograft function were recipients of 
cadaveric kidneys. Cyclosporine-treated patients bad signifi-
cantiy lower rates of renal function recovery (P = 0.026) and 
lower creatinine clearance values (P = 0.005) than 
azathioprine-treated patients (Table 3). No consistent dif-
ferences in preservation techniques, time from harvest to trans-
plantation, or in the age of donors were noted between 
cyclosporine- and azathioprine-treated recipients of cadaveric 
grafts. 
Because the early stages of type 1 diabetes mellitus are char-
acterized by increased glomerular filtration rates, the effect 
of diabetes on the rate of renal function recovery was assessed 
in a subset of type 1 diabetic patients (n = 7) treated with 
cyclosporine who had received a cadaveric renal allograft. The 
rate of renal function recovery was higher in diabetic patients 
(6.8 ± 2.2 mL/min/day) when compared to control patients 
(4.2 ± 1.3 mL/min/day) but did not reach statistical significance 
(P = 0.069). No differences were noted in the number of days 
required to achieve steady renal function (8.5 ± 1.7 and 7.7 ± 
1.9 days for control and diabetic patients, respectively; P = not 
significant). Creatinine clearance values were also similar in 
both groups (39 ± 4 versus 41 ± 3 mL/min for control and dia-
betic patients, respectively; P = not significant). 
Discussion 
Cyclosporine is an important addition to the immunosup-
pressive regimens used in renal transplantation and has resulted 
in significant improvements in graft survival (1-3). However, 
cyclosporine-induced nephrotoxicity, both short- and long-
term, is an important side effect that warrants close observation 
(4-7). Researchers have also suggested that cyclosporine may 
aggravate ischemic renal injury (9-11). The purpose of this study 
was to determine the effect of cyclosporine therapy in the early 
post renal transplantation period on the rate of renal function re-
covery in the absence of clinical rejection. In this way the direct 
effect of cyclosporine on immediate and delayed renal allograft 
function could be better evaluated clinically. 
Assessment of renal function by estimation of creatinine 
clearance using single-pool creatinine kinetics allows the daily 
assessment of renal function without the difficulties inherent in 
daily urine collections in a routine clinical setting. Although a 
close correlation was observed between actual creatinine clear-
ance measurements and those estimated by kinetic modeling 
(Figure), it could be argued that the calculated values are not ac-
curate. However, the coefficient of variation between measured 
and estimated values was 8.26%—a value acceptable for 
clinical practice. In addition, the purpose of this study was not to 
define the absolute rates of renal function recovery but to com-
pare these rates in relation to treatment and donor type. Any de-
viation of the estimated clearance value when compared to ac-
tual measurements would be systematic and equally applicable 
to all groups. 
As expected, the rate of renal function recovery was better in 
recipients of organs from living, related donors compared to re-
cipients of cadaveric grafts (Table 2). These findings were inde-
pendent of the type of immunosuppressive regimen used (Table 
2). The number of days to a stable creatinine clearance was also 
less in those who received organs from living, related donors 
when compared to cadaveric-graft recipients (Table 2). How-
ever, even in this eariy posttransplantation period, reduced renal 
function was apparent in cadaveric-graft recipients treated with 
cyclosporine compared to those treated with azathioprine (Table 
2). This effect occurred at low serum cyclosporine trough levels 
(150 to 200 ng/mL) which are known to result in better preserva-
tion of renal function than protocols aiming for higher levels (2). 
Although others have addressed the issue of the effect of 
cyclosporine on early graft function (17-19), no data were pro-
vided on the rate of renal function recovery. These reports have 
dealt mostly with the prevalence of acute tubular necrosis post-
transplantation and its resolution. The present study confirms 
that cyclosporine therapy decreases the rate of recovery in pa-
tients with delayed allograft function as well as provides a quan-
titative measure of such an effect (Table 3). Thus, posttransplant 
acute tubular necrosis is necessary to demonstrate the negative 
effect of cyclosporine on the rate of renal function recovery. 
These results suggest that renal vasoconstriction (a cyclosporine 
effect) and/or tubular damage (whether or not related to 
cyclosporine) may result in decreased graft function in the eariy 
post renal transplant period. 
Although creatinine clearance measurements demonstrated 
significant differences between azathioprine- and cyclosporine-
treated patients with immediate renal allograft function, serum 
creatinine values did not reach statistical significance. Serum 
creatinine concentration is a function of lean body mass, and its 
elimination is mainly by glomerular filtration rate. Thus, when 
comparing individuals with differing lean body mass, creatinine 
clearance is a more accurate comparative measurement of renal 
function than serum creatinine concentration. 
Since the eariy stages of type 1, insulin-dependent diabetes 
mellitus are characterized by hyperfiltration (20,21), the rate of 
improvement in renal function was compared in cyclosporine-
treated type 1 diabetic and nondiabetic patients who had 
received a cadaveric allograft. Although the recovery rate was 
1.6 times greater in type 1 diabetic patients than in nondiabetic 
patients, the results were not statistically significant. However, 
because of the need to stratify by donor type and treatment reg-
imen, this negative finding may be related more to sample size 
rather than to lack of a biological effect. Altematively, the use of 
cyclosporine may abolish diabetic-induced hyperfiltration. 
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Cyclosporine treatment has no effect on the recovery rate of 
renal allograft function in the absence of clinical rejection and 
posttransplant acute tubular necrosis. In patients with delayed 
allograft function, cyclosporine treatment decreases the rate 
of renal function recovery. However, even in this early 
postoperative period, patients receiving cyclosporine achieve 
a lower level of renal function than those treated with 
azathioprine. 
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